After a rainy bank holiday weekend, the four-day week was jam-packed with action for the Optimum team, as our client Calliditas recommended shareholders accept a $1 billion+ takeover offer. Calliditas receives public offer by Asahi Kasei Corporation Asahi Kasei Corporation announced on Tuesday a public cash offer to acquire all shares and American Depositary Receipts […]
The great and the good of biotech descended on San Sebastian, Spain, for the influential Bio€quity Europe conference, one of the major dealmaking and networking events of the year. Despite inclement weather, the conference was sold out, allowing CEOs and investors to gather, network, partner and debate issues facing the biotech industry. Representatives of the […]
From a major international investment event, to a new way to use the complement system to fight cancer, here’s what Optimum and its clients have been doing this week. Novo Nordisk Foundation, Wellcome, and the Bill & Melinda Gates Foundation join forces to accelerate global health equity and Novo Nordisk Foundation gives grants for global […]
It’s May already, and Optimum Strategic Communications and its clients have had their foot on the gas this week as we head into the summer months. Poolbeg signs exclusive option agreement to acquire orphan drug candidate for Behçet’s Disease Poolbeg Pharma, a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases […]
The current optimistic mood in biotech was reflected in a string of positive announcements from Optimum and its clients. SynOx completes $75m Series B financing to fund cancer mAb SynOx Therapeutics Limited, the late-stage clinical biopharmaceutical company, on Monday announced the close of a $75m Series B financing. The financing was co-led by Forbion, HealthCap […]
